Clene Inc. (CLNN): who owns it and who trades it
As of Nov 16, 2026, CLNN insiders reported 62 open-market sales worth $5.8M and 1 purchase worth $217K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chidozie Ugwumba (10% owner), with $5.8M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Clene
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CLNN
33 funds and institutions reported CLNN shares worth $19.6M at the end of Q2 2026, about 27% of the company. The largest holder is Empery Asset Management, LP with 7.8%.
Funds and institutions (13F) 27%Everyone else 73%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Empery Asset Management, LP | 916,532 | 7.78% | $5.6M | New |
| Scoggin Management LP | 600,000 | 5.09% | $3.7M | +100% |
| Boxer Capital Management, LLC | 477,515 | 4.05% | $2.9M | No change |
| Ensign Peak Advisors, Inc | 348,062 | 2.96% | $2.1M | +35% |
| Vanguard Capital Management LLC | 333,706 | 2.83% | $2.1M | +8% |
| Geode Capital Management, LLC | 102,215 | 0.87% | $630K | +7% |
| BlackRock, Inc. | 61,559 | 0.52% | $379K | +82% |
| Vanguard Fiduciary Trust Co | 57,765 | 0.49% | $356K | +32% |
| Lunt Capital Management, Inc. | 52,260 | 0.44% | $322K | No change |
| Parsons Capital Management Inc | 37,243 | 0.32% | $229K | No change |
| Peak6 LLC | 30,012 | 0.25% | $185K | -40% |
| State Street Corp | 29,801 | 0.25% | $183K | No change |
| Morgan Stanley | 19,858 | 0.17% | $122K | +0% |
| Northern Trust Corp | 19,723 | 0.17% | $121K | +22% |
| Hrt Financial LP | 18,321 | 0.16% | $112K | New |
| ADAR1 Capital Management, LLC | 15,000 | 0.13% | $92.3K | New |
| Arax Advisory Partners | 11,140 | 0.09% | $68.6K | +1854% |
| Penn Davis Mcfarland Inc | 11,000 | 0.09% | $67.7K | No change |
| Jane Street Group, LLC | 10,203 | 0.09% | $62.8K | New |
| Wells Fargo & Company | 5,927 | 0.05% | $36.5K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CLNN insiders reported $217K of open-market purchases and $5.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | Chidozie Ugwumba | 10% owner | Sale | 73,296 | $6.20 | $454K | Form 4 |
| May 11, 2026 | Chidozie Ugwumba | 10% owner | Sale | 22,177 | $6.75 | $150K | Form 4 |
| May 4, 2026 | Chidozie Ugwumba | 10% owner | Sale | 72,884 | $6.80 | $496K | Form 4 |
| May 1, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,795 | $6.01 | $34.8K | Form 4 |
| Apr 30, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,736 | $6.08 | $34.9K | Form 4 |
| Apr 29, 2026 | Chidozie Ugwumba | 10% owner | Sale | 12,170 | $5.63 | $68.5K | Form 4 |
| Apr 28, 2026 | Chidozie Ugwumba | 10% owner | Sale | 1,591 | $5.90 | $9.4K | Form 4 |
| Apr 21, 2026 | Chidozie Ugwumba | 10% owner | Sale | 61,345 | $6.14 | $377K | Form 4 |
| Apr 20, 2026 | Chidozie Ugwumba | 10% owner | Sale | 4,318 | $6.12 | $26.4K | Form 4 |
| Apr 17, 2026 | Chidozie Ugwumba | 10% owner | Sale | 25,040 | $6.43 | $161K | Form 4 |
| Apr 16, 2026 | Chidozie Ugwumba | 10% owner | Sale | 7,748 | $6.40 | $49.6K | Form 4 |
| Apr 15, 2026 | Chidozie Ugwumba | 10% owner | Sale | 6,374 | $6.48 | $41.3K | Form 4 |
| Apr 2, 2026 | Chidozie Ugwumba | 10% owner | Sale | 24,925 | $4.81 | $120K | Form 4 |
| Apr 1, 2026 | Chidozie Ugwumba | 10% owner | Sale | 4,278 | $4.97 | $21.3K | Form 4 |
| Mar 31, 2026 | Chidozie Ugwumba | 10% owner | Sale | 67,991 | $4.88 | $332K | Form 4 |
| Mar 30, 2026 | Chidozie Ugwumba | 10% owner | Sale | 15,536 | $5.10 | $79.2K | Form 4 |
| Mar 27, 2026 | Chidozie Ugwumba | 10% owner | Sale | 17,470 | $4.75 | $83K | Form 4 |
| Mar 26, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,319 | $5.40 | $28.7K | Form 4 |
| Mar 25, 2026 | Chidozie Ugwumba | 10% owner | Sale | 7,098 | $5.50 | $39K | Form 4 |
| Mar 24, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,492 | $5.78 | $31.7K | Form 4 |
| Feb 3, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,559 | $4.10 | $22.8K | Form 4 |
| Feb 2, 2026 | Chidozie Ugwumba | 10% owner | Sale | 3,800 | $4.04 | $15.4K | Form 4 |
| Jan 30, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,686 | $4.13 | $23.5K | Form 4 |
| Jan 29, 2026 | Chidozie Ugwumba | 10% owner | Sale | 15,284 | $4.32 | $66K | Form 4 |
| Jan 28, 2026 | Chidozie Ugwumba | 10% owner | Sale | 8,717 | $4.91 | $42.8K | Form 4 |
| Jan 27, 2026 | Chidozie Ugwumba | 10% owner | Sale | 4,139 | $5.08 | $21K | Form 4 |
| Jan 26, 2026 | Chidozie Ugwumba | 10% owner | Sale | 6,418 | $5.02 | $32.2K | Form 4 |
| Jan 23, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,556 | $5.27 | $29.3K | Form 4 |
| Jan 22, 2026 | Chidozie Ugwumba | 10% owner | Sale | 12,665 | $5.32 | $67.4K | Form 4 |
| Jan 21, 2026 | Chidozie Ugwumba | 10% owner | Sale | 12,119 | $5.05 | $61.2K | Form 4 |
| Jan 20, 2026 | Chidozie Ugwumba | 10% owner | Sale | 12,432 | $4.80 | $59.7K | Form 4 |
| Jan 16, 2026 | Chidozie Ugwumba | 10% owner | Sale | 7,923 | $5.13 | $40.6K | Form 4 |
| Jan 15, 2026 | Chidozie Ugwumba | 10% owner | Sale | 12,563 | $5.10 | $64.1K | Form 4 |
| Jan 14, 2026 | Chidozie Ugwumba | 10% owner | Sale | 19,621 | $5.12 | $100K | Form 4 |
| Jan 13, 2026 | Chidozie Ugwumba | 10% owner | Sale | 26,105 | $4.89 | $128K | Form 4 |
| Jan 13, 2026 | David J Matlin | Director | Purchase | 33,333 | $6.50 | $217K | Form 4 |
| Jan 12, 2026 | Chidozie Ugwumba | 10% owner | Sale | 32,705 | $5.50 | $180K | Form 4 |
| Jan 9, 2026 | Chidozie Ugwumba | 10% owner | Sale | 9,075 | $6.27 | $56.9K | Form 4 |
| Jan 8, 2026 | Chidozie Ugwumba | 10% owner | Sale | 3,195 | $6.09 | $19.5K | Form 4 |
| Jan 7, 2026 | Chidozie Ugwumba | 10% owner | Sale | 3,938 | $6.29 | $24.8K | Form 4 |
| Jan 6, 2026 | Chidozie Ugwumba | 10% owner | Sale | 3,111 | $6.04 | $18.8K | Form 4 |
| Jan 5, 2026 | Chidozie Ugwumba | 10% owner | Sale | 5,869 | $5.87 | $34.5K | Form 4 |
| Jan 2, 2026 | Chidozie Ugwumba | 10% owner | Sale | 4,015 | $5.73 | $23K | Form 4 |
| Dec 31, 2025 | Chidozie Ugwumba | 10% owner | Sale | 13,095 | $5.81 | $76.1K | Form 4 |
| Dec 30, 2025 | Chidozie Ugwumba | 10% owner | Sale | 4,138 | $6.03 | $25K | Form 4 |
| Dec 29, 2025 | Chidozie Ugwumba | 10% owner | Sale | 8,096 | $5.95 | $48.2K | Form 4 |
| Dec 26, 2025 | Chidozie Ugwumba | 10% owner | Sale | 3,350 | $6.32 | $21.2K | Form 4 |
| Dec 24, 2025 | Chidozie Ugwumba | 10% owner | Sale | 1,490 | $6.27 | $9.3K | Form 4 |
| Dec 23, 2025 | Chidozie Ugwumba | 10% owner | Sale | 6,831 | $6.27 | $42.8K | Form 4 |
| Dec 22, 2025 | Chidozie Ugwumba | 10% owner | Sale | 4,367 | $6.54 | $28.6K | Form 4 |
| Dec 19, 2025 | Chidozie Ugwumba | 10% owner | Sale | 5,582 | $6.45 | $36K | Form 4 |
| Dec 18, 2025 | Chidozie Ugwumba | 10% owner | Sale | 5,816 | $6.33 | $36.8K | Form 4 |
| Dec 17, 2025 | Chidozie Ugwumba | 10% owner | Sale | 2,884 | $6.61 | $19.1K | Form 4 |
| Dec 16, 2025 | Chidozie Ugwumba | 10% owner | Sale | 7,030 | $6.31 | $44.4K | Form 4 |
| Dec 15, 2025 | Chidozie Ugwumba | 10% owner | Sale | 10,580 | $6.49 | $68.7K | Form 4 |
| Dec 12, 2025 | Chidozie Ugwumba | 10% owner | Sale | 7,603 | $6.79 | $51.6K | Form 4 |
| Dec 11, 2025 | Chidozie Ugwumba | 10% owner | Sale | 10,907 | $6.81 | $74.3K | Form 4 |
| Dec 10, 2025 | Chidozie Ugwumba | 10% owner | Sale | 9,921 | $6.42 | $63.7K | Form 4 |
| Dec 9, 2025 | Chidozie Ugwumba | 10% owner | Sale | 15,031 | $5.95 | $89.4K | Form 4 |
| Dec 8, 2025 | Chidozie Ugwumba | 10% owner | Sale | 21,463 | $5.70 | $122K | Form 4 |
| Dec 5, 2025 | Chidozie Ugwumba | 10% owner | Sale | 37,235 | $5.94 | $221K | Form 4 |
| Dec 4, 2025 | Chidozie Ugwumba | 10% owner | Sale | 72,748 | $6.73 | $490K | Form 4 |
| Dec 3, 2025 | Chidozie Ugwumba | 10% owner | Sale | 56,577 | $7.86 | $445K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Chidozie Ugwumba | 10% owner | – | $5.8M | May 12, 2026 |
| David J Matlin | Director | $217K | – | Jan 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CLNN short interest
Low short interest. 3.2% of CLNN shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went down 68%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 416,980 CLNN shares were sold short, 3.2% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 82,334 shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 416,980 | 3.25% | -2% | 82,334 | 5.1 |
| Oct 15, 2026 | 424,864 | 3.31% | -52% | 94,981 | 4.5 |
| Sep 30, 2026 | 880,688 | 6.85% | -4% | 117,415 | 7.5 |
| Sep 15, 2026 | 915,634 | 7.13% | -5% | 177,656 | 5.2 |
| Aug 31, 2026 | 965,618 | 7.52% | -4% | 54,676 | 17.7 |
| Aug 14, 2026 | 1.01M | 7.85% | +6% | 105,094 | 9.6 |
| Jul 31, 2026 | 947,551 | 8.04% | +2% | 65,651 | 14.4 |
| Jul 15, 2026 | 925,388 | 7.86% | -6% | 50,232 | 18.4 |
| Jun 30, 2026 | 988,908 | 8.40% | -6% | 101,618 | 9.7 |
| Jun 15, 2026 | 1.06M | 8.97% | -6% | 102,124 | 10.3 |
| May 29, 2026 | 1.13M | 9.56% | -15% | 117,109 | 9.6 |
| May 15, 2026 | 1.32M | 11.23% | +51% | 2.26M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Clene company events
Clene filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 20, 2026AgreementPreviously, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced (i) on October 5, 2023, a four-year, $45.1 million grant from the National Institute of Health to the Company, in collaboration with… Filing
- Oct 19, 2026AnnouncementClene Inc. issued a press release announcing its New Drug Application submission to the U.S. Food and Drug Administration for CNM-Au8 for the treatment of amyotrophic lateral sclerosis. Filing
- Sep 16, 2026AgreementClene Inc. entered into a securities purchase agreement with certain existing stockholders, including certain of the Company’s directors and officers, pursuant to which the Company agreed to issue and sell an aggregate of 1,219,513 shares of the Company’s common stock, par value $0.0001 per share… Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 10, 2026AnnouncementThe Company issued a press release announcing biomarker analyses to be included in the Company’s NDA submission supporting ALS accelerated approval. Filing
- May 22, 2026LeadershipThe stockholders of the Company voted at the Company’s 2026 Annual Meeting of Stockholders to approve the Clene Inc. Amended 2020 Stock Plan to increase the number of shares of common stock, par value $0.0001 per share reserved for issuance thereunder by 1,000,000 shares. Filing
- May 14, 2026AgreementClene Inc. entered into the second amendment to the amended and restated senior secured convertible promissory notes with Kensington Clene 2024, LLC, 4Life Research, LLC and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “Holders”). Filing
- May 5, 2026AgreementClene Inc. entered into an underwriting agreement with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, at an offering price of $7.00 per share. Filing
- May 4, 2026AnnouncementAs previously reported, the FDA granted to the Company a Type C in-person meeting to, among other things, discuss the ability of the Company to file an NDA for ALS under an accelerated approval pathway. Filing
- Mar 17, 2026AgreementPreviously, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced (i) on October 5, 2023, a four-year, $45.1 million grant from the National Institute of Health to the Company, in collaboration with… Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementClene Inc. issued a press release announcing a letter to stockholders highlighting upcoming CNM-Au8 2026 catalysts. Filing
- Jan 13, 2026AgreementClene Inc. entered into a securities purchase agreement with certain institutional investors, existing stockholders of the Company, and certain of the Company’s directors for the sale of (i) 928,333 shares of the Company’s common stock, par value $0.0001 per share, (ii) warrants to purchase up to… Filing
- Jan 12, 2026AnnouncementClene Inc. issued a press release announcing additional CNM-Au8 ® biomarker data supporting a potential new drug application filing for an upcoming in-person meeting with the U.S. Food and Drug Administration. Filing
- Dec 3, 2025AnnouncementShared information with investors. Filing
- Dec 3, 2025AnnouncementClene Inc. issued a press release announcing statistically significant amyotrophic lateral sclerosis biomarker results supporting an accelerated approval pathway for CNM-Au8. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Clene financials
Famous investors that hold CLNN
1 of the 50 well-known investors we track reported holding CLNN in their latest 13F filing. The largest position is Ken Griffin's, worth $469K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 114,847 | $469K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CLNN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 13, 2026 | Empery Asset Management, LP | 13G/A | 1.6% |
| Oct 13, 2026 | Empery Asset Management, LP | 13G/A | 1.6% |
Questions about Clene Inc. (CLNN) stock
Who owns the most CLNN stock?
The largest reported owner of Clene Inc. (CLNN) is Empery Asset Management, LP, with 7.8% of the company. In total, 33 funds and institutions reported holding CLNN at the end of Q2 2026, together about 27% of the shares. See the largest owners.
Are CLNN insiders buying or selling?
In the last 12 months, CLNN insiders reported 1 open-market purchase worth $217K and 62 sales worth $5.8M. The latest trade was on May 12, 2026. See every trade.
What is the short interest in CLNN?
As of Oct 30, 2026, 416,980 CLNN shares were sold short, 3.2% of the shares outstanding, down 1.9% from the report before. At the average daily volume of 82,334 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold CLNN?
1 of the 50 well-known investors we track reported CLNN in their latest 13F filing, including Ken Griffin. The largest position is worth $469K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.